Back to top
more

Option Care Health (OPCH)

(Delayed Data from NSDQ)

$29.61 USD

29.61
1,759,663

+0.32 (1.09%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $29.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

by Zacks Equity Research

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

by Zacks Equity Research

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Aurora Cannabis (ACB) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Aurora Cannabis' (ACB) sustained consumer cannabis sales are likely to have benefited its performance in the fiscal second quarter.

Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by net dialysis and the related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the fourth quarter.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed a recovery in rapid immunoassay revenues during Q4.

InMode (INMD) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.

Canopy Growth (CGC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal third quarter.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) patient volumes are expected to have increased significantly in the fourth quarter due to pent-up demand.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.

Will Encompass Health (EHC) Gain From Inpatient Rehab Business?

by Zacks Equity Research

Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.

Encompass Health (EHC) to Spin Off Unit to Streamline Business

by Zacks Equity Research

Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.

Option Care Health's (OPCH) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Option Care Health (OPCH).

Encompass Health (EHC) to Build Rehabilitation Hub in Illinois

by Zacks Equity Research

Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.

Option Care (OPCH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 125.00% and 7.41%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?